Sign in
Taking peopleNo phase

Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children

Key facts

Who runs it
S-Alpha Therapeutics, Inc.
Where
South Korea5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
40 people, planned
Started
16 Dec 2024
Planned end
30 Jul 2026
Type of study
Observational, 2 groups
Treatments tested
  • Single vision spectacles
Record updated
9 January 2025

Who can take part

Age
5 years to 8 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participants who have completed the previous clinical trial (SAT001-KP-002), and their legal guardians who agree to participate in this extension study and are willing to provide the signed informed consent after receiving and comprehending the explanation of the description of this clinical trial (subject under 6 can make a mark for agreement after full information and understanding)

Who cannot take part

  • Participants in the study group of the previous clinical trial (SAT001-KP-002) with a compliance rate of less than 70% (overall compliance throughout the study period)
  • Other reasons for participation in the trial at the discretion of the investigator

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 5 and 8 years old?

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objective of this clinical trial is to collect data on the rebound effect and long-term safety of SAT-001, a Software as a Medical Device (SaMD) under development for the inhibition and treatment of myopia progression in pediatric patients.

The 2 groups in the trial

  • Arm 1: Spectacles with Cessation of SAT-001 Use

    This group consists of pediatric participants who were previously assigned to receive SAT-001 along with single vision spectacles as part of the SAT-001 confirmatory trial (SAT-001-KP-002). In the extension phase, these participants will continue wearing single vision spectacles, but will no longer receive SAT-001 treatment. The aim is to monitor rebound myopia and long-term safety after the completion of the initial trial, focusing on any changes in refractive error and axial length, as well as any adverse effects associated with the cessation of SAT-001 use.

    Treatment: Single vision spectacles

  • Arm 2: Continued Spectacles Only

    This group consists of pediatric participants who were assigned to the control group during the SAT-001 confirmatory trial and received only single vision spectacles. In the extension phase, they will continue wearing spectacles to assess rebound myopia and long-term safety, without the addition of SAT-001 treatment.

    Treatment: Single vision spectacles

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Open-label, Controlled Extension Study to Evaluate the Rebound Effect and Long-term Safety of Software SAT-001 for the Inhibition of Myopia Progression and Treatment in Pediatric Patients With Myopia
Criteria questions
Built from NCT06742268, who can take part
Record updated
9 January 2025